{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:02:07Z","timestamp":1753894927657,"version":"3.41.2"},"reference-count":32,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Survival of patients with Hodgkin\u2019s lymphoma is lower in in low- and middle-income countries, but factors leading to these outcomes are poorly understood. The objective of this study was to identify predictive factors associated with overall survival among cancer patients undergoing therapy in seven low- and middle-income countries.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A multicenter cohort was conducted in Egypt, Malaysia, Mexico, Peru, Philippines, Thailand\u00a0and Ukraine. Results. A total of 460 patients were included. Phone-based support during patient follow-up and number of patients seen by the physician provided a positive impact, while the number of adverse events remains a predictor of death and physician decision to stop treatment.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Furthers research on the potential benefit of phone-based programs to support patients with chronic diseases treatments should be explored in less developed countries.\n          <\/jats:p>","DOI":"10.57264\/cer-2022-0210","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T18:34:05Z","timestamp":1686076445000},"source":"Crossref","is-referenced-by-count":0,"title":["Phone contacts and treatment discontinuation predict survival cancer patients in a subsidized drug access program"],"prefix":"10.57264","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-8457","authenticated-orcid":false,"given":"Jo\u00ebl","family":"Ladner","sequence":"first","affiliation":[{"name":"Epidemiology &amp; Health Promotion Department, Rouen University Hospital, Rouen, 76000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Madi","sequence":"additional","affiliation":[{"name":"Axios International Consultants Ltd, Dubai, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshel","family":"Jayasundera","sequence":"additional","affiliation":[{"name":"Axios International, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Saba","sequence":"additional","affiliation":[{"name":"Axios International, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Audureau","sequence":"additional","affiliation":[{"name":"Paris Est Universit\u00e9, h\u00f4pital Henri Mondor H\u00f4pital, Public Heath, Assistance Publique H\u00f4pitaux de Paris, Cr\u00e9teil, 94000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1532\/IJH97.05184","article-title":"Epidemiology and pathologic features of Hodgkin lymphoma","volume":"83","author":"Shin-ichi N","year":"2006","unstructured":"Shin-ichi N. Epidemiology and pathologic features of Hodgkin lymphoma. Int. J. Hematol. 83(5), 391\u2013397 (2006).","journal-title":"Int. J. Hematol."},{"key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-019-0799-1","article-title":"Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study","volume":"12","author":"Zhou L","year":"2019","unstructured":"Zhou L, Deng Y, Li N Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J. Hem. Onc. 12, 107 (2019).","journal-title":"J. Hem. Onc."},{"key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-021-00198-2","article-title":"A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990-2017","volume":"10","author":"Keykhaei M","year":"2021","unstructured":"Keykhaei M, Masinaei M, Mohadmmadi E A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990-2017. Exp. Hematol. Oncol. 10, 11 (2021).","journal-title":"Exp. Hematol. Oncol."},{"key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3322\/caac.21597","article-title":"Enhancing global access to cancer medicines","volume":"70","author":"Cortes J","year":"2020","unstructured":"Cortes J, Perez-Garcia JM, Llombart-Cussac A Enhancing global access to cancer medicines. CA Cancer J. Clin. 70, 105\u2013124 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott JS","year":"2017","unstructured":"Scott JS. Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma. Drugs 77, 435\u2013445 (2017).","journal-title":"Drugs"},{"issue":"1","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-137089","article-title":"Brentuximab vedotin with chemotherapy for patients with previously untreated stage III\/IV classical Hodgkin lymphoma: 5-year updated of the ECHELON-1 study","volume":"136","author":"Strauss DJ","year":"2020","unstructured":"Strauss DJ, Dlugosz-Danecka M, Connoer JM Brentuximab vedotin with chemotherapy for patients with previously untreated stage III\/IV classical Hodgkin lymphoma: 5-year updated of the ECHELON-1 study. Blood 136(Suppl. 1), 26\u201328 (2020).","journal-title":"Blood"},{"issue":"10","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.6004\/jnccn.2019.7314","article-title":"Physician experience and risk of rituximab discontinuation in older adults with non-Hodgkin's lymphoma","volume":"17","author":"Huntington SF","year":"2019","unstructured":"Huntington SF, Hoag JR, Wang R Physician experience and risk of rituximab discontinuation in older adults with non-Hodgkin's lymphoma. J. Natl Compr. Canc. Netw. 17(10), 1194\u20131202 (2019).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1200\/JCO.2009.22.0038","article-title":"Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study","volume":"27","author":"Loberiza FR","year":"2009","unstructured":"Loberiza FR, Cannon AJ, Weisenburger DD Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J. Clin. Oncol. 27, 5376\u20135382 (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy","volume":"13","author":"Velasco R","year":"2021","unstructured":"Velasco R, Domingo-Domenech E, Sured A. Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy. Cancers 13, 6125 (2021).","journal-title":"Cancers"},{"issue":"9","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/13696998.2018.1484372","article-title":"Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future","volume":"21","author":"Atieno OM","year":"2018","unstructured":"Atieno OM, Opanga S, Martin A, Kurdi A, Godman B. Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future. J. Med. Econ. 21(9), 878\u2013887 (2018).","journal-title":"J. Med. Econ."},{"issue":"4","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14737167.2020.1794826","article-title":"Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review","volume":"21","author":"Al-Ziftawi NH","year":"2021","unstructured":"Al-Ziftawi NH, Shafie AA, Ibrahim MIM. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Rev. Pharmacoecon. Outcomes Res. 21(4), 655\u2013666 (2021).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12962-019-0174-7","article-title":"Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer","volume":"17","author":"Gershon N","year":"2019","unstructured":"Gershon N, Berchenko Y, Hall PS, Goldstein DA. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Eff. Resour. Alloc. 17, 5 (2019).","journal-title":"Cost Eff. Resour. Alloc."},{"issue":"4","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14737167.2021.1884546","article-title":"Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications","volume":"21","author":"Godman B","year":"2021","unstructured":"Godman B, Hill A, Simoens S Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev. Pharmacoecon. Outcomes Res. 21(4), 527\u2013540 (2021).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1002\/cam4.3483","article-title":"Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: evidence from the real-world setting","volume":"9","author":"Coquet J","year":"2020","unstructured":"Coquet J, Blayney DW, Brooks JD, Hernandez-Boussard T. Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: evidence from the real-world setting. Cancer Med. 9, 8552\u20138561 (2020).","journal-title":"Cancer Med."},{"key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12913-021-06552-8","article-title":"Telephone follow-up of oncology patients: the contribution of the nurse specialist for a Service-Dominant Logic in hospital","volume":"21","author":"Rochette C","year":"2021","unstructured":"Rochette C, Michallet AS, Malartre-Sapienza S, Rodier S. Telephone follow-up of oncology patients: the contribution of the nurse specialist for a Service-Dominant Logic in hospital. BMC Health Services Res. 21, 580 (2021).","journal-title":"BMC Health Services Res."},{"issue":"8","key":"e_1_3_6_19_2","first-page":"835","article-title":"Telehealth interventions for supportive management and early recognition of treatment-related symptoms in patients with hematologic malignancies","volume":"12","author":"Yajima C","year":"2021","unstructured":"Yajima C, Bowe C, Barber D, Dains J. Telehealth interventions for supportive management and early recognition of treatment-related symptoms in patients with hematologic malignancies. J. Adv. Pract. Oncol. 12(8), 835\u2013849 (2021).","journal-title":"J. Adv. Pract. Oncol."},{"issue":"2","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/pop.2012.0049","article-title":"Development and validation of a multilateral index to determine economic status in developing countries: the Patient Financial Eligibility Tool (PFET)","volume":"16","author":"Saba J","year":"2013","unstructured":"Saba J, Audureau E, Bize M, Koloshuk B, Ladner J. Development and validation of a multilateral index to determine economic status in developing countries: the Patient Financial Eligibility Tool (PFET). Popul. Health Manag. 16(2), 82\u201389 (2013).","journal-title":"Popul. Health Manag."},{"key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"e003097","DOI":"10.1136\/bmjopen-2013-003097","article-title":"Effects of telephone community-recruited chronic obstructive pulmonary disease on self-management capacity, quality of life and psychological morbidity: a randomised controlled trial","volume":"3","author":"Walters J","year":"2013","unstructured":"Walters J, Cameron-Tucker H, Wills K Effects of telephone community-recruited chronic obstructive pulmonary disease on self-management capacity, quality of life and psychological morbidity: a randomised controlled trial. BMJ Open 3, e003097 (2013).","journal-title":"BMJ Open"},{"issue":"3","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/pop.2015.0049","article-title":"The impact of a telephone-based chronic disease management program on medical expenditures","volume":"19","author":"Avery G","year":"2016","unstructured":"Avery G, Cook D, Talens S. The impact of a telephone-based chronic disease management program on medical expenditures. Popul. Health Manag. 19(3), 156\u2013162 (2016).","journal-title":"Popul. Health Manag."},{"issue":"3","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1071\/AH13005","article-title":"Do people with existing chronic conditions benefit from telephone coaching? A rapid review","volume":"37","author":"Dennis SM","year":"2013","unstructured":"Dennis SM, Harris M, Lloyd J Do people with existing chronic conditions benefit from telephone coaching? A rapid review. Aust. Health Rev. 37(3), 381\u2013388 (2013).","journal-title":"Aust. Health Rev."},{"key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejon.2017.03.002","article-title":"A qualitative study of the post-treatment experiences and support needs of survivors of lymphoma","volume":"28","author":"Monterosso L","year":"2017","unstructured":"Monterosso L, Taylor K, Platt V A qualitative study of the post-treatment experiences and support needs of survivors of lymphoma. Eur. J. Oncol. Nurs. 28, 62\u201368 (2017).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0177"},{"issue":"9","key":"e_1_3_6_26_2","first-page":"1","article-title":"Self-management support interventions for persons with chronic disease: an evidence-based analysis","volume":"13","author":"Franek J","year":"2013","unstructured":"Franek J. Self-management support interventions for persons with chronic disease: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 13(9), 1\u201360 (2013).","journal-title":"Ont. Health Technol. Assess. Ser."},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0738-3991(02)00032-0","article-title":"Self-management approaches for people with chronic conditions: a review","volume":"48","author":"Barlow J","year":"2002","unstructured":"Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people with chronic conditions: a review. Patient Educ. Counsel. 48, 177\u2013187 (2002).","journal-title":"Patient Educ. Counsel."},{"key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pec.2013.02.009","article-title":"Self-management: one size does not fit all","volume":"92","author":"Trappenburg J","year":"2013","unstructured":"Trappenburg J, Jaarsma T, van Os-Medendorp H, Kort H, Hoes A, Schuurmans M. Self-management: one size does not fit all. Patient Educ. Counsel. 92, 134\u2013137 (2013).","journal-title":"Patient Educ. Counsel."},{"key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41533-020-0188-9","article-title":"A cohort study of medication adherence among patients with chronic obstructive pulmonary disease in Egypt","volume":"30","author":"Ladner J","year":"2020","unstructured":"Ladner J, El Badrawy M, Nofal A, Saba J, Audureau E. A cohort study of medication adherence among patients with chronic obstructive pulmonary disease in Egypt. NPJ Prim. Care Respir. Med. 30, 31 (2020).","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM199603143341106","article-title":"Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival","volume":"334","author":"Kitahata MM","year":"1996","unstructured":"Kitahata MM, Koepsell TD, Deyo RA, Maxewell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N. Engl. J. Med. 334, 701\u2013706 (1996).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1503\/cmaj.060124","article-title":"The impact of physician training and experience on the survival of patients with active tuberculosis","volume":"175","author":"Kamran K","year":"2006","unstructured":"Kamran K, Campbell A, Wallington T, Gardam M. The impact of physician training and experience on the survival of patients with active tuberculosis. Can. Med. Assoc. J. 175(7), 749\u2013753 (2006).","journal-title":"Can. Med. Assoc. J."},{"key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jval.2016.11.028","article-title":"Patient versus physician evaluation of durable survival gains: implications for value framework assessments","volume":"20","author":"Shafrin J","year":"2017","unstructured":"Shafrin J, Schwart TT, Okoro T, Romley JA. Patient versus physician evaluation of durable survival gains: implications for value framework assessments. Value Health 20, 217\u2013223 (2017).","journal-title":"Value Health"},{"key":"e_1_3_6_33_2","doi-asserted-by":"crossref","unstructured":"World Health Organization Model List of Essential Medicines \u2013 22nd List 2021. World Health Organization Switzerland (2021). https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2021.02","DOI":"10.1530\/ey.19.13.1"},{"issue":"6","key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2022.01.023","article-title":"Electronic patient symptom management program to support patients receiving cancer treatment at home during the COVID-19 pandemic","volume":"25","author":"Wujcik D","year":"2022","unstructured":"Wujcik D, Dudley WN, Dudley M, Gupta V, Brant J. Electronic patient symptom management program to support patients receiving cancer treatment at home during the COVID-19 pandemic. Value Health 25(6), 931\u2013936 (2022).","journal-title":"Value Health"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2022-0210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:27:53Z","timestamp":1688124473000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.57264\/cer-2022-0210"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0210","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2023,7]]},"article-number":"e220210"}}